China Biologic Products (CBPO) received a $120 per share offer to take the company private. The newly elected CEO has a lot of expertise in the M&A market, which we believe is ideal. He will most likely know how to maximize value for shareholders. Also, the company may need to look for potential buyers, which could pay a bit more than $120 per share. We believe that the company is undervalued. Thus, industrial players could be interested.
Source: 10-K
Business
Founded in December 1898, China Biologic Products commenced selling human plasma-based biopharmaceutical products